- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels
Qing-Lei Zeng, Zu-Jiang Yu, Jia Shang, Guang-Hua Xu, Chang-Yu Sun, Na Liu, Chun-Xia Li, Jun Lv, Yan-Min Liu, Hong-Xia Liang, Zhi-Qin Li, Ya-Jie Pan, Qiu-Yue Hu, Wei Li, Da-Wei Zhang, Fu-Sheng Wang
Author Notes
Open Forum Infectious Diseases, Volume 7, Issue 6, June 2020, ofaa208, https://doi.org/10.1093/ofid/ofaa208
Published:
03 June 2020
Article history
pdfPDF
Split View
Cite
Permissions Icon Permissions
Share
Abstract
Background
None of the current guidelines recommend antiviral therapy for inactive hepatitis B virus (HBV) carriers (IHCs).
Methods
In this real-world, multicenter, nonrandomized study, 32 participants meeting the inclusion criteria were enrolled 1:1 for treatment with peginterferon α-2b or monitoring without treatment based on participant preference. The expected treatment duration was 48 weeks. The primary end point was hepatitis B surface antigen (HBsAg) loss. The HBV vaccine could be injected after HBsAg loss.
Results
All patients had HBsAg levels of <20 IU/mL. The mean baseline HBsAg levels were 6.6 IU/mL and 5.8 IU/mL in the treated and untreated groups, respectively. Fifteen (93.8%) participants achieved HBsAg loss, 5 obtained HBsAg seroconversion after undergoing a mean of 19.7 weeks of therapy in the treated group, and no one in the follow-up group achieved HBsAg loss during a mean follow-up time of 12.6 months (P < .0001). Generally, the therapy was well tolerated. Nine of 11 individuals who exhibited HBsAg loss benefited from receiving the HBV vaccine.
Conclusions
This study provides justification for further studies of short-course peginterferon α-2b for the functional cure of IHCs with low HBsAg levels. Additionally, HBV vaccine injection is beneficial after interferon-induced HBsAg loss.
functional cure, hepatitis B surface antigen loss, hepatitis B vaccine, inactive hepatitis B virus carrier, peginterferon α-2b
Topic:
surface antigens follow-up hepatitis b surface antigens hepatitis b, chronic hepatitis b virus viruses hepatitis b vaccines peginterferon
Issue Section:
Major Article |
|